GLOBAL - NITAG - NETWORK

NITAG Resource Center

Downloaded on 24 November 2026

This PDF reflects the content available on the download date. Consult the **web version** for any updates.

# Measles containing vaccines indicator

## Acceptability to stakeholders

### Acceptability of the vaccine and of vaccination against the disease

In low- and middle-income countries where measles mortality is high, measles vaccination is acceptable to most key stakeholders.[1]

Rubella vaccine is provided together with measles, mumps, and varicella in various combinations. Therefore, acceptability is generally high because it does not require an additional injection or visit.[2] As of 2025, 179 out of 194 Member States have introduced an RCV and global coverage is estimated at 73%. The remaining countries are mostly LICs and serve as reservoirs for the virus.[3]

Acceptability of mumps vaccine is generally high as it is administered as part of measles-containing combination vaccines (MMR or MMRV) and does not require an additional injection of vaccination visit. As of 2025, 124 WHO Member States have introduced mumps-containing vaccine into their routine immunization programmes. However, there remains some low- and middle-income countries that continue to use MR vaccine only.[4] Decisions to include mumps-containing vaccines usually rely on country epidemiology, health system capacity, and competing priorities.[4]

Please consult the relevant position papers for intervention safety for varicella.

## Sources


1.

World Health Organization. Evidence to Recommendation Framework for measles vaccines. 2017 (https://cdn.who.int/media/docs/default-source/immunization/position_paper_documents/measles/measles-evidence-recommendation.pdf?sfvrsn=29e89774_2, accessed 7 August 2026).

2.

World Health Organization. Rubella vaccines: WHO position paper – July 2020. Wkly Epidemiol Rec. 2020;95(27):306–324. (https://www.who.int/publications/i/item/WHO-WER9527, accessed 1 August 2026).

3.

Lebo E, Vynnycky E, Alexander JP Jr, Ferrari MJ, Winter AK, Frey K, et al. Estimated current and future congenital rubella syndrome incidence with and without rubella vaccine introduction—19 countries, 2019–2055. MMWR Morb Mortal Wkly Rep. 2024;73(41):930–936. doi:10.15585/mmwr.mm7341a2.

4.

World Health Organization. Strategic Advisory Group of Experts on Immunization (SAGE) Yellow Book: September 2023. Geneva: World Health Organization; 2023. ( https://terrance.who.int/mediacentre/data/sage/SAGE_eYB_Sept2023.pdf, accessed 7 August 2026).